CBSA to honor life science innovators, leaders tonight

CBSA to honor life science innovators, leaders tonight

DENVER -- Colorado BioScience Association (CBSA) will highlight a banner year marked by acquisitions, investments, discoveries and partnerships during its 14 th Annual Awards Dinner tonight in... Read More

Thursday November 9, 2017 0 comments Tags: Denver, CBSA, April Giles, Array BioPharma, miRagen Therapeutics, Sharklet Technologies, Cerescan, Eximis Surgical, Ocugen, Boettcher Foundation

Array BioPharma to raise $225M through stock sale

Array BioPharma to raise $225M through stock sale

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) announced the pricing of an underwritten public offering of 20,930,232 shares of its common stock at a public offering price of$10.75per share. ... Read More

Friday September 15, 2017 0 comments Tags: Boulder, Array BioPharma

Array BioPharma announces FDA acceptance to review new melanoma drug applications

Array BioPharma announces FDA acceptance to review new melanoma drug applications

BOULDER -- Array BioPharma (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Applications (NDAs) to support use of the combination of... Read More

Wednesday September 13, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, encorafenib, binimetinib

Array BioPharma and Amgen collaborate to develop autoimmune drugs

Array BioPharma and Amgen collaborate to develop autoimmune drugs

BOULDER/THOUSAND OAKS, Calif. -- California-based Amgen (NASDAQ:AMGN) and Boulder-based Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development... Read More

Wednesday July 19, 2017 0 comments Tags: Boulder, Array BioPharma, Amgen, Nicholas Saccomano, Flavius Martin

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

BOULDER -- Array BioPharma (Nasdaq:ARRY) today announced the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) to support use of the combination of... Read More

Wednesday July 5, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, binimetinib, encorafenib

Array BioPharma and Bristol-Myers Squibb announce strategic research collaboration

Array BioPharma and Bristol-Myers Squibb announce strategic research collaboration

BOULDER andNEW YORK CITY -- Array BioPharma (Nasdaq: ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) announced the companies have entered into a clinical research collaboration to investigate... Read More

Thursday June 1, 2017 0 comments Tags: Boulder, Array BioPharma, Bristol-Myers Squibb, Ron Squarer, Fouad Namouni

Array BioPharma announces strategic collaboration with Merck

Array BioPharma announces strategic collaboration with Merck

BOULDER -- Array BioPharma Inc .(Nasdaq: ARRY) announced it has entered into a clinical trial collaboration agreement with Merck (known as MSD outsidethe United StatesandCanada) to investigate... Read More

Tuesday May 9, 2017 0 comments Tags: Boulder, Array BioPharma, Merck, Ron Squarer, binimetinib, KEYTRUDA

Array BioPharma closes on stock sale raising $132.25M

Array BioPharma closes on stock sale raising $132.25M

BOULDER -- Array BioPharma Inc . (NasdaqGM: ARRY) today announced the closing of its underwritten public offering of 21,160,000 shares of its common stock, which includes 2,760,000 shares of... Read More

Wednesday October 5, 2016 0 comments Tags: Boulder, Array BioPharma